DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Medicare & Medicaid Services

7500 Security Boulevard

Baltimore, Maryland 21244-1850

**MEDICARE-MEDICAID COORDINATION OFFICE**

**DATE:** August 08, 2022

**TO:**  Minnesota Senior Health Options Dual Eligible Special Needs Plans

**FROM:** Lindsay P. Barnette

Director, Models, Demonstrations, and Analysis Group

**SUBJECT:** Release of Final Contract Year 2023 Marketing Guidance for Minnesota Senior Health Options Dual Eligible Special Needs Plans

Attached to this memorandum is the final Contract Year (CY) 2023 Marketing Guidance for Minnesota Senior Health Options (MSHO) Dual Eligible Special Needs Plans (D-SNPs) operating in the Minnesota Demonstration to Align Administrative Functions for Improvements in Beneficiary Experience demonstration. CMS and Minnesota jointly updated the Marketing Guidance for MSHO D-SNPs, in accordance with provisions of the Three-Way Contract.

All Medicare Advantage-Prescription Drug (MA-PD) plan sponsor requirements in 42 CFR Parts 422 and 423 as well as all MA-PD plan sponsor requirements in the Medicare Communications and Marketing Guidelines (MCMG), posted at [www.cms.gov/Medicare/Health-Plans/ManagedCareMarketing/FinalPartCMarketingGuidelines](https://www.cms.gov/Medicare/Health-Plans/ManagedCareMarketing/FinalPartCMarketingGuidelines) apply to MSHO D-SNPs participating in the Minnesota capitated financial alignment model demonstration, except as clarified or modified in this Marketing Guidance. In addition, the Centers for Medicare and Medicaid Services (CMS) recently codified guidance on May 9, 2022,[[1]](#footnote-1) which also applies to MSHO D-SNPs except as clarified in the Marketing Guidance. The Marketing Guidance is applicable to all MSHO D-SNPs marketing for CY 2023 benefits.

We will post the attached Marketing Guidance to the Medicare-Medicaid Coordination Office webpage at [www.cms.gov/Medicare-Medicaid-Coordination/Medicare-and-Medicaid-Coordination/Medicare-Medicaid-Coordination-Office/FinancialAlignmentInitiative/MMPInformationandGuidance/MMPMarketingInformationandResources](https://www.cms.gov/Medicare-Medicaid-Coordination/Medicare-and-Medicaid-Coordination/Medicare-Medicaid-Coordination-Office/FinancialAlignmentInitiative/MMPInformationandGuidance/MMPMarketingInformationandResources), grouped alphabetically by state under the “State-Specific Information” heading.

For any questions about the contents of this memorandum, please contact your Contract Management Team or the Medicare-Medicaid Coordination Office at [MMCOCapsModel@cms.hhs.gov](mailto:MMCOCapsModel@cms.hhs.gov).

1. Refer to Contract Year 2023 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Programs; Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency; Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency, which may be found in the Final Rule published on May 9, 2022 ([www.federalregister.gov/documents/2022/05/09/2022-09375/medicare-program-contract-year-2023-policy-and-technical-changes-to-the-medicare-advantage-and](https://www.federalregister.gov/documents/2022/05/09/2022-09375/medicare-program-contract-year-2023-policy-and-technical-changes-to-the-medicare-advantage-and)). [↑](#footnote-ref-1)